Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During ...

Ousted CDC director Susan Monarez says Kennedy planned to change pediatric vaccine schedule; Eli Lilly’s obesity pill beats Novo’s Rybelsus in latest study; Novo views semaglutide trial in Alzheimer’s ...

Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.

Novo NordiskNVO stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.